This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition
by Zacks Equity Research
FDA approves Lilly's Omvoh for Crohn's disease, expanding its use to the second major type of IBD condition.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
by Sundeep Ganoria
Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales growth of its tirzepatide products in Q4.
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip
by Sweta Killa
Eli Lilly slashes the revenue guidance for the fourth quarter and fiscal 2024 but offers a bullish outlook for 2025.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4
by Zacks Equity Research
LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates.
The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular
by Zacks Equity Research
J&J, Eli Lilly, GSK and Intra-Cellular are included in this Analyst Blog.
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference
by Kinjel Shah
J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.
AbbVie Falls 8% in 3 Months: Buy, Hold or Sell the Stock?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $797.48, moving -0.3% from the previous trading session.
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?
by Shaun Pruitt
Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy
by Zacks Equity Research
Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.
LLY Falls Around 14% in 3 Months: How to Play the Stock
by Kinjel Shah
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug
by Zacks Equity Research
The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.
Why the Market Dipped But Eli Lilly (LLY) Gained Today
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day.
Sanofi Down 10% in 3 Months: How Should You Play the Stock?
by Kinjel Shah
SNY's reasonable valuation, improving top-line performance, contributions from new product launches and positive pipeline progress are good enough reasons to stay invested in the stock
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer Rises 5.6% in a Month: How Should You Play the Stock?
by Kinjel Shah
Investors may stay invested in PFE stock to see how its new growth drivers perform
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
by Zacks Equity Research
Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.
5 Large Drug Stocks to Keep An Eye On in the New Year
by Kinjel Shah
R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
by Sundeep Ganoria
Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Why Eli Lilly (LLY) Dipped More Than Broader Market Today
by Zacks Equity Research
Eli Lilly (LLY) reachead $773.84 at the closing of the latest trading day, reflecting a -1.19% change compared to its last close.
J&J Trading Near 52-Week Low: Should You Sell the Stock?
by Kinjel Shah
Those who own the stock may stay invested for some time as J&J looks optimistic about a better performance in 2025.
Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY
by Kinjel Shah
NVO's novel obesity candidate shows lower-than-expected weight loss in the study. FDA approves LLY's Zepbound for sleep apnea.